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Abstract
Background: Few studies have investigated the periodontal condition among Rheumatoid arthritis in Sudan. The
present study described the periodontal condition among Sudanese patients suffering from rheumatoid arthritis
and to compare them with those of non-rheumatic subjects.
Methods: A group of eighty rheumatoid arthritis patients was selected from Patient’s Rheumatoid Clinics in
Khartoum State during the period of January to May 2010. A control group of eighty patients with the same age
and gender was selected for the study. Both Rheumatoid arthritis patients and the control group were examined
for their plaque index, gingival index, and clinical attachment loss.
Results: The results revealed that there were no significant differences in plaque and gingival index among study
and control groups, with mean plaque index of (1.25 ± 0.4) for patients and (1.17 ± 0.28) for the control group (p-
value is 0.3597). The mean gingival index was (1.2 ± 0.24) for the patients and (1.2 ± 0.33) for the control (p = is
0.3049). The results showed statistically significant differences in clinical attachment loss between study and control
groups, with mean clinical attachment loss of (1.03 ± 0.95) for the study group and (0.56 ± 0.63) for the control
group (p = 0.0002). The study revealed that no association exists between the type of drug used to treat
rheumatoid arthritis (NSAIDs & DMARDs) and the periodontal parameters (plaque index, gingival index, and clinical
attachment loss).
Conclusion: A significant relationship between periodontal disease and Rheumatoid Arthritis does exist, but no
difference between plaque and gingival index has been detected among study and control groups.
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Background
The oral cavity is thought to be the window to the body
because oral manifestations accompany many systemic
diseases [1]. Periodontitis is a common disease world-
wide that has a primary bacterial etiology and is charac-
terized by dysregulation of the host inflammatory
response which eventually results in soft and hard tissue
destruction [2,3]
Rheumatoid arthritis (RA) is a chronic destructive
inflammatory disease characterized by the accumulation
and persistence of an inflammatory infiltrate in the
synovial membrane that leads to synovitis and the
destruction of the joint architecture [2].
Rheumatoid arthritis (RA) occurs worldwide with pre-
valence of 1% in the population, most common in
females [4], affecting women three times more than
men [5,6]. It is estimated that arthritis and other rheu-
matic conditions affect 42.7 million Americans [7] with
prevalence of 0.5 to 1% in Western population [8].
While the etiology of these two diseases may differ,
the underlying pathogenic mechanisms are remarkably
similar and it is possible that individuals manifesting
both periodontitis and RA may suffer from a unifying
underlying systemic dysregulation of the inflammatory
response [2]. There is almost universal acceptance that a
variety of cytokines and matrix metalloproteinases
(MMPs) are upregulated and intimately involved in the
pathogenesis of both periodontitis and RA; many of
these effector molecules appear to be common to both
diseases [3]. High levels of proinflammatory cytokines,
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a), and low levels of cytokines which suppress the
immunoinflammatory response, such as IL-10 and trans-
forming growth factor-b (TGF-b), have been detected in
periodontitis as well as in Rheumatoid Arthritis [9].
Natural history studies of periodontal disease in
humans indicate the presence of three distinct subpopu-
lations: [10].
1) no progression of periodontal disease, in which
around 10% of the population manifest very little or no
disease which is of particular consequence to dentition;
2) moderate progression, affecting around 80% of the
population and representing a very slowly progressing
form of disease that generally can be easily managed via
routine therapies; and 3) rapid progression, affecting
approximately 8% of individuals whereby extensive peri-
odontal destruction occurs which can be very difficult to
control.
On the other hand, three types of disease manifesta-
tions can also be observed in RA populations:
1) Self-limited: in these cases, individuals originally
presenting for RA have no evidence of disease 3 to 5
years later; [11].
2) Easily controlled: the disease is relatively easily con-
trolled with only non-steroidal anti-inflammatory drugs
(NSAIDs); [12]
3) Progressive: these patients generally require second-
line drugs, which often still do not fully control the dis-
ease [13].
It must be recognized that periodontitis differs in one
significant way from RA through our understanding that
the subgingival biofilm is a key etiologic factor in peri-
odontitis. Unlike periodontal disease, no specific bacter-
ial etiology has been identified for RA. Thus, while host
modifications of disease processes are possible for peri-
odontitis, controlling the bacteria that cause periodontal
infections remains a significant focus for periodontal
treatment and prevention. Host modification can be
only an adjunct treatment for periodontitis. However,
until an etiologic factor can be found for RA, host mod-
ification remains the primary treatment [3].
Currently, the first line of treatment for RA is NSAIDs
such as aspirin, naproxen, diclofenac, and ibuprofen.
Their mechanism of action through the inhibition of
Cyclooxygenase (COX) synthesis produces both analge-
sic and antipyretic properties. Although these medica-
tions are effective in reducing the pain symptoms in RA,
they do not significantly alter its course [14].
The use of NSAIDs for the treatment of chronic peri-
odontitis has been studied over the past 20 years [15].
While the results appear promising, the widespread clin-
ical use of these medications to alter the course of peri-
odontitis has not been universal. Their use for the
management of periodontitis appears to be a ‘’rebound’’
effect to baseline following a cessation of the medication
[16].
With the discovery of two COX enzymes responsible
for PGE2 production, designated COX-1 and COX-2, a
variety of COX-2 inhibitors have been studied for their
potential to stop or slow down bone resorption. One of
the first COX-2 inhibitors developed, Tenidap, has been
shown to inhibit not only cyclooxygenase and PGE2
production but also IL-1, IL-6, and TNF-a production.
To date, the potential of COX-2 inhibitors to modify
bone resorption in periodontitis have not been thor-
oughly studied [3].
In contrast to NSAIDS, which do not significantly
alter the course of RA, a newer family of medications
designated as disease-modifying anti-rheumatic drugs
(DMARDs) has been developed. This medication has
demonstrated an ability to change the course of RA for
at least one year as evidenced by sustained improvement
in function, decreased synovitis, and prevention of
further joint damage [17]. Examples of these medica-
tions include parenteral gold salts, methotrexate, sulfasa-
lazine, hydroxychloroquine (antimalarial drug),
penicillamine, azathioprine, and leflunomide. A major
drawback in the use of DMARDs is their considerable
toxicity [18].
The use of DMARDs for the management of period-
ontitis has been restricted largely due to the toxicity
issues. However, the use of gold salts in an animal
model has shown reduced periodontal destruction [19].
Till now, no human studies have been performed.
The relationship between rheumatoid arthritis (RA)
and periodontitis is controversial. Many studies that
have been done present conflicting results regarding the
relationship between periodontitis and RA. However, a
significant association between these two common
chronic diseases has been reported recently [20,21].
RA is a common disease in Sudan, [22] and the litera-
ture correlating the severity of RA and the severity of
periodontal disease is insufficient. This study was
designed to investigate the periodontal status and in RA
patients and to find if there is an association between
RA and periodontal disease among patients in Khar-
toum State.
Methods
Eighty Rheumatoid arthritis patients (RA) aged 20 -60
years old were examined at the common rheumatoid
arthritis clinics in Khartoum State (University of Medi-
cal Sciences and Technology, Elribat University Hospital
and Ibrahim Malik Teaching Hospital). All patients had
intertmittently been taking various kinds of NSAIDs for
long periods, some of them occasionally in conjunction
with chloroquines. A group of eighty healthy individuals
matched in age and gender was selected as a control
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centers.
Inclusion criteria
Study group
- Patients (20-60 years old) diagnosed with RA with
consideration of the disease duration.
- Willingness of the patient to participate in the study.
- Only partially (at least 8 teeth excluding 3
rd molar)
or fully dentate patients were included in the study.
Control group
- Age group 20 - 60 years old
- Absence of rheumatoid arthritis, diabetes, hyperten-
sion and blood dyscriasis. This was determined by test-
ing random blood sugar levels, measuring the blood
pressure and doing a complete blood count for each
patient prior to the examination.
- Willingness to participate in the study
- Only partially (at least eight teeth, excluding 3
rd
molar) or fully dentate patients were selected in the
control group.
Exclusion criteria included pregnancy, lactation, smok-
ing, periodontal therapy or antibiotics in the previous
three months, or any systemic condition which might
have affected the progression of periodontitis. No sub-
jects with localized or generalized aggressive periodonti-
tis were included in this study.
Each subject who met the inclusion criteria completed
a questionnaire, which gathered information on their
demographic background. Approval for the research was
obtained from the Research Ethics Committee of the
Faculty of Dentistry University of Khartoum. Aims of
the investigation and the nature of the study were fully
explained to the subjects, who gave their informed writ-
ten consent before participation.
All periodontal examinations were made with Michi-
gan O periodontal probes with a controlled force of
0.2N by one examiner (Kamil S). Clinical measurements
were made at four sites (mesiobuccal-distobuccal),
(mesio lingual-distolingual) of all teeth, excluding third
molars. Plaque Index (PI) [23] and Gingival Index (GI)
[24] were used for detection of plaque and gingival
inflammation respectively. Michigan O periodontal
probe was used for measurement of pocket depth and
clinical attachment level.
Statistical analysis
Standard descriptive statistical techniques were used to
summarize and present sample information. To check
for possible significant differences in periodontal status
between the case and control group, the t-test was used
for normally distributed data. In case of non-normal
data, the Mann-Whitney test was used. The data was
processed using STATA software package (version10).
Results
The data of this study was collected over a period of five
months from three rheumatoid arthritis centers in Khar-
toum State. The results revealed that there were no sig-
nificant differences in plaque and gingival index among
study and control, with mean plaque index of (1.25 ±
0.4) for patients and (1.17 ± 0.28) for the control group
(p = 0.3597). The mean gingival index was (1.2 ± 0.24)
for the patients and (1.2 ± 0.33) for the control (p =
0.3049) (Figure 1, 2).
There was a statistically significant difference in the
mean pocket depth between the study and the control
group, a mean pocket depth of > 4 mm was observed in
10% of subjects in the RA group compared to 1.25% in
the control group (table 1).
The results showed statistically significant differences
in clinical attachment loss between study and control
groups, with mean clinical attachment loss of (1.03 ±
0.95) for the study group and (0.56 ± 0.63) for the con-
trol group p = 0.0002 (table-2).
From the study, there was no significant correlation
b e t w e e nd u r a t i o no fi l l n e s sa n dp l a q u ei n d e x( p=
0.9786), gingival index (p = 0.9079), and clinical attach-
m e n tl o s s( p=0 . 0 9 3 3 )a t0 . 0 5l e v e lo fs i g n i f i c a n c e
(table-3).
The study also revealed that no association exists
between the drugs used to treat rheumatoid arthritis
(NSAIDs & DMARDs) and the periodontal parameters
(plaque index, gingival index, probeable pocket depth
and clinical attachment loss) (table-4).
Discussion
In this study, 72 females and 8 males participated (9:1).
This ratio is greater than previous studies in other
Figure 1 Mean plaque index for study and control group.
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more likely to develop RA than males [25]. The present
study reveals that there is no statistically significant dif-
ference in the plaque index between Ruematoid Arthritis
patients and the control group (p = 0.524), and this is in
agreement with Mercado F.B et al [21] and Yaniv et al
[26]. Thus, the general concept that RA patients tend to
have more plaque deposits because of limited dexterity
was not validated. However Ishi et al [27] and Ezel et al
[28] demonstrate a high prevalence of sites with dental
plaque in their studies, and this may be explained by the
fact that those patients directed their attention mainly to
their serious illness while neglecting their oral health.
No significant difference has been found in the Gingi-
val index when comparing the study group with the con-
trol group (p = 0.3049). This is similar to the findings
reported by Mercado et al [21] and Ishi et al [27], but it
disagrees with the findings by Yaniv et al [26] which
found higher prevalence of sites with gingival inflamma-
tion in the RA patients compared with the control group.
There was a statistically significant difference in the
mean pocket depth between the study and the control
group. A mean pocket depth of > 4 mm was observed
in 10% for the study group versus 1.25% for the control
group, which indicated presence of deeper pocket depth
in the RA patients. These results agreed with Mercado
et al [21], Mikael et al [29], N pischon et al [8] and Yniv
et al [26].
A significant difference has been observed in the clini-
cal attachment level of study and control groups l (p =
0.002). The results agree with Ishi et al [27], Mikael et
al [29] and Depablo et al, [30] and this may be due to
increased secretion of pro-inflammatory mediators in
both conditions.
Our findings showed that a relationship may exist
between periodontitis and RA. This association is prob-
ably due to a common dysregulation of the immune-
inflammatory response in these patients, despite their
different etiology. In both conditions, there are a num-
ber of possible pathways of similar dysregulation, includ-
ing characteristics of innate and acquired immune
systems. Neutrophils play an important role in the
pathogenesis of both diseases, and an aberrant neutro-
philic response has been described, RA and periodontitis
[31]. Another common pathogenic link affecting period-
ontitis and RA is the monocytic hypersecretory state
[11], which may induce the secretion of excessive pro-
inflammatory cytokine secretion, such as IL-1b, TNF-a
and IL-6, which results in the stimulation of degrading
enzymes and tissue destruction. The role of helper T
lymphocytes has also been evaluated [32], it has been
suggested that T-cell characteristics in periodontal dis-
eases may resemble, in some respects, those in RA, a
condition in which tissue destruction is mediated by a T
helper 1 (Th1) cytokine profile. Some studies point to a
genetic component in the susceptibility to RA and peri-
odontitis. Associations with HLA subtypes and genes
outside the HLA region, such as genetic polymorphisms
of some cytokines, may contribute to susceptibility to
both diseases [33,34].
This study shows no association between the drugs
used for treatment of rheumatoid arthritis (NSAIDs &
DMARDs) and the periodontal parameters (plaque
index, gingival index, and clinical attachment loss). This
agreed with findings of Gleissner et al [35], who found
no correlation between the duration of pharmacotherapy
and periodontal parameters, but it disagreed with Ezel et
al [28] who found that medication including NSAIDs
and corticosteroids may decrease gingival inflammation.

Figure 2 Mean gingival index for study and control group.
Table 1 Comparison of the probeable pocket depth
(per millimeters) between study and control groups
Cases (N = 80) Controls (N = 80) P Value*
≤ 0.5 52 (65%) 77 (96.25%) 0.000
> 0.5 to ≤ 1 20 (25%) 2 (2.5%)
>1t o≤ 1.5 5 (6.25%) 1 (1.25%)
> 1.5 3 (3.75%) 0 (0%)
Mean ± SD 0.46 ± 0.42 0.15 ± 0.22 0.000
Table 2 Comparison of clinical attachment loss (per
millimeters) between study group and control group
Cases (N = 80) Controls (N = 80) P Value*
≤ 1.17 52 (65%) 70 (87.5%) 0.006
> 1.17 to ≤ 2.33 20 (25%) 7 (8.75%)
> 2.33 to ≤ 3.5 5 (6.25%) 3 (3.75%)
> 3.5 3 (3.75%) 0 (0%)
Mean ± SD 1.03 ± 0.95 0.56 ± 0.62 0.0002
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duration of illness and periodontal destruction, although
many RA patients take medications that can reduce per-
iodontal destruction (i.e., NSAIDs). This may indicate
that prior to the development of RA symptoms, the per-
iodontitis was most likely developing and not detected.
Conclusion
The results indicated a significant relationship between
periodontal disease and RA. However no significant dif-
ference between plaque and gingival index has been
detected among study and control groups. This study
highlights the potential for a relationship between two
of the most common and debilitating chronic inflamma-
tory conditions affecting the Sudanese population and
warrants further detailed investigation.
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